CN116323649A - 膜联蛋白a1 n-末端肽的制剂和方法 - Google Patents

膜联蛋白a1 n-末端肽的制剂和方法 Download PDF

Info

Publication number
CN116323649A
CN116323649A CN202180050871.2A CN202180050871A CN116323649A CN 116323649 A CN116323649 A CN 116323649A CN 202180050871 A CN202180050871 A CN 202180050871A CN 116323649 A CN116323649 A CN 116323649A
Authority
CN
China
Prior art keywords
liquid pharmaceutical
solution
annexin
pharmaceutical formulation
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180050871.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·T·布克林斯基
P·S·图隆
M·H·闫森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lesoth Pharmaceutical Co ltd
Original Assignee
Lesoth Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lesoth Pharmaceutical Co ltd filed Critical Lesoth Pharmaceutical Co ltd
Publication of CN116323649A publication Critical patent/CN116323649A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202180050871.2A 2020-08-21 2021-08-20 膜联蛋白a1 n-末端肽的制剂和方法 Pending CN116323649A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20192142 2020-08-21
EP20192142.6 2020-08-21
PCT/EP2021/073186 WO2022038281A1 (en) 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods

Publications (1)

Publication Number Publication Date
CN116323649A true CN116323649A (zh) 2023-06-23

Family

ID=72193322

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180050871.2A Pending CN116323649A (zh) 2020-08-21 2021-08-20 膜联蛋白a1 n-末端肽的制剂和方法

Country Status (10)

Country Link
US (2) US20230295255A1 (cg-RX-API-DMAC10.html)
EP (3) EP4595950A3 (cg-RX-API-DMAC10.html)
JP (1) JP2023539476A (cg-RX-API-DMAC10.html)
CN (1) CN116323649A (cg-RX-API-DMAC10.html)
AU (1) AU2021327733A1 (cg-RX-API-DMAC10.html)
CA (1) CA3192030A1 (cg-RX-API-DMAC10.html)
ES (1) ES3031633T3 (cg-RX-API-DMAC10.html)
HU (1) HUE071875T2 (cg-RX-API-DMAC10.html)
PL (1) PL4200319T3 (cg-RX-API-DMAC10.html)
WO (2) WO2022038258A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3031633T3 (en) * 2020-08-21 2025-07-10 Resother Pharma As Annexin a1 n-terminal peptide formulations and methods
US20250345392A1 (en) 2022-06-30 2025-11-13 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition
EP4680262A1 (en) 2023-03-13 2026-01-21 Resother Pharma A/S Annexin a1 delayed dosing
AU2024234229A1 (en) 2023-03-13 2025-09-25 Resother Pharma A/S Annexin a1 administration regime
WO2025083394A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of annexin a1 protein
WO2025083393A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of peptides derived from annexin a1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
BR112013032088B1 (pt) 2011-06-15 2020-11-24 Resother Pharma Aps produtos farmacêuticos anti-inflamatórios
WO2013053888A1 (en) * 2011-10-14 2013-04-18 Baxter International Inc. Protein purification by anion exchange chromatography
HUE052977T2 (hu) 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
CN110302176A (zh) * 2019-06-25 2019-10-08 中国人民解放军陆军军医大学 一种抗炎多肽纳米药物及制备方法
ES3031633T3 (en) * 2020-08-21 2025-07-10 Resother Pharma As Annexin a1 n-terminal peptide formulations and methods
US20250345392A1 (en) * 2022-06-30 2025-11-13 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition

Also Published As

Publication number Publication date
EP4200319C0 (en) 2025-04-16
EP4200319B1 (en) 2025-04-16
AU2021327733A9 (en) 2023-04-27
CA3192030A1 (en) 2022-02-24
US20230295255A1 (en) 2023-09-21
EP4200319A1 (en) 2023-06-28
WO2022038258A1 (en) 2022-02-24
AU2021327733A1 (en) 2023-04-20
EP4595950A2 (en) 2025-08-06
JP2023539476A (ja) 2023-09-14
ES3031633T3 (en) 2025-07-10
PL4200319T3 (pl) 2025-08-18
HUE071875T2 (hu) 2025-09-28
EP4595950A3 (en) 2025-10-29
EP4200320A1 (en) 2023-06-28
US20240041977A1 (en) 2024-02-08
WO2022038281A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
EP4200319B1 (en) Annexin a1 n-terminal peptide formulations and methods
TWI642682B (zh) 升糖素類似物
MX2007000510A (es) Composiciones para suministrar peptido yy y agonistas de pyy.
CN105705160B (zh) Il-22二聚体在制备用于治疗胰腺炎的药物中的用途
JP7580404B2 (ja) Ｇｌｐ１／２二重アゴニストの非経口医薬組成物
JP6069663B2 (ja) 抗炎症医薬製品
TWI921427B (zh) Glp-1/glp-2雙重促效劑之醫藥組合物
JP7751641B2 (ja) Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
TW202241491A (zh) Ｇｌｐ－１／ｇｌｐ－２雙重促效劑之醫藥組合物
RU2470666C2 (ru) Фармацевтическая композиция для трансназального введения
CN115605218B (zh) 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物
RU2852511C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2855486C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2855506C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
JP2001522814A (ja) 増大されたｉｇｆ−ｉ溶解性を提供する組成物
US20230272024A1 (en) Fibroblast growth factor 7 peptide
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK1223556B (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination